Anti-TF Antibodies With Distinct Epitope Binding for Coagulation Sparing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-TF antibodies and antibody-drug conjugates often inhibit human thrombin generation and interfere with the TF/FVIIa complex, leading to unintended effects on coagulation processes and angiogenesis in cancer and other diseases.
Innovation Solution
Development of antibodies that bind to a distinct site on human TF, inhibiting FVIIa-dependent TF signaling and do not inhibit human thrombin generation, allowing thrombin generation while avoiding interference with the TF/FVIIa complex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-TF antibodies bind to TF, then they can inhibit TF-mediated processes, but they also inhibit human thrombin generation and interfere with TF/FVIIa complex
Solution Approach 1:
The antibody is designed to bind to a specific local region (epitope) on the TF extracellular domain that is distinct from the FVIIa binding site. This localized binding approach allows the antibody to target TF specifically without interfering with the TF/FVIIa complex formation, thereby maintaining thrombin generation while achieving TF-specific inhibition of pathological processes.
Solution Approach 2:
The TF protein is functionally segmented into distinct binding regions: the FVIIa binding site and other regions on the extracellular domain. The antibody targets a specific segment (epitope) that does not overlap with the FVIIa binding site, allowing selective inhibition of certain TF-mediated processes while preserving the coagulation function through intact TF/FVIIa complex formation.
2Reliability
If antibodies inhibit TF/FVIIa signaling, then they can reduce angiogenesis and tumor progression, but they also interfere with normal coagulation processes
Solution Approach 1:
The antibody binds to a specific epitope on the TF extracellular domain that is spatially distinct from the FVIIa binding site. This localized binding enables selective disruption of TF-mediated angiogenic signaling while leaving the TF/FVIIa coagulation complex formation unaffected, thereby achieving therapeutic efficacy without compromising normal coagulation function.
3Reliability
If antibodies bind to TF at the FVIIa binding site, then they can effectively block TF activity, but they prevent thrombin generation
Solution Approach 1:
The antibody is engineered to bind to a specific epitope on the TF extracellular domain that is anatomically distinct from the FVIIa binding site. This spatial separation of binding sites allows the antibody to exert its inhibitory effect on TF-mediated processes while permitting normal FVIIa binding and subsequent thrombin generation to proceed uninterrupted.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies maintain normal thrombin generation and coagulation processes, reducing angiogenesis and metastasis in cancer without interfering with TF/FVIIa activity, thus providing a targeted therapeutic approach.
Implementation Method 1
an isolated human antibody which binds to the extracellular domain of human Tissue Factor (TF), wherein the antibody binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FVIIa
Data Source
AI summary
Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the antibodies or ADCs, such as therapeutic and diagnostic methods.